Medshine Discovery describes new EGFR triple mutant inhibitors for NSCLC
Jan. 12, 2024
Medshine Discovery Inc. has identified EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
